Welcome to our dedicated page for Verona Pharma plc SEC filings (Ticker: VRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Verona Pharma plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Verona Pharma plc's regulatory disclosures and financial reporting.
Form 4 filed by David R. Ebsworth, Director of Verona Pharma plc (VRNA) dated 08/05/2025 reporting transactions on 08/01/2025. The report discloses a grant of RSUs covering 24,000 Ordinary Shares (presented as the Ordinary Share equivalent of ADS-based RSUs) and a mandatory "sell-to-cover" sale of 1,904 Ordinary Shares at $13.1437 per share to satisfy tax withholding upon vesting. The RSUs vest 25% on each of Aug 1, 2025; Nov 1, 2025; Feb 1, 2026; and May 1, 2026 and have no expiration. Following the reported transactions the filing shows direct beneficial ownership of 880,499 Ordinary Shares and indirect ownership of 617,600 Ordinary Shares via Ebsworth GmbH. Form signed by attorney-in-fact on 08/05/2025.
Form 4 filing for Verona Pharma plc (VRNA) by Director Anders Ullman reporting an RSU award and resulting holdings.
On 08/01/2025 Ullman received an award of 24,000 Restricted Share Units (RSUs) expressed as the equivalent number of Ordinary Shares underlying ADSs, at a reported price of $0. Each RSU represents a contingent right to receive one ADS; each ADS represents 8 Ordinary Shares. Following the transaction Ullman beneficially owns 358,856 Ordinary Shares (reported as 44,857 ADSs) and holds 72,000 derivative securities reported as RSUs. The RSUs have no expiration and vest 25% on Aug 1, 2025, Nov 1, 2025, Feb 1, 2026 and May 1, 2026, subject to continued service. Form signed by attorney-in-fact Andrew Fisher on 08/05/2025.
Merck Sharp & Dohme LLC has filed a DFAN14A on behalf of Verona Pharma (VRNA) as part of the ongoing merger process. The filing consists of an internal e-mail and video transcript sent 30 Jul 2025 to all Verona employees. Key takeaways:
- Deal timing: Merck reiterates that the acquisition is expected to close later in 2025, subject to Verona shareholder approval and sanction by the U.K. High Court.
- Work-force retention: Virtually every Verona employee (excluding some executives) will receive a retention agreement by end-Aug; signatures are due 19 Sep and are contingent on deal completion.
- Strategic rationale: Verona’s COPD drug Ohtuvayre is positioned as a critical growth driver within Merck’s multiyear optimisation initiative, underscoring the buyer’s commitment to invest in pipeline, products and people.